|
Jun 11
|
Top Midday Decliners
|
|
Jun 11
|
Cabaletta Bio Announces Pricing of Public Offering of Securities
|
|
Jun 11
|
Cabaletta Bio Announces Proposed Public Offering of Securities
|
|
Jun 11
|
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
|
|
May 29
|
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
|
|
May 20
|
Biotech Alert: Searches spiking for these stocks today
|
|
Feb 26
|
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
|
|
Feb 18
|
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
|
|
Feb 18
|
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
|
|
Feb 11
|
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
|
|
Jun 14
|
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
|
|
May 22
|
We Think Cabaletta Bio (NASDAQ:CABA) Can Afford To Drive Business Growth
|
|
May 15
|
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 13
|
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
|
|
Mar 23
|
Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway
|
|
Mar 21
|
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
|
Mar 20
|
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
|
|
Mar 8
|
Jim Cramer’s 10 Latest Stock Picks This Week
|
|
Jan 9
|
Are Investors Undervaluing Cabaletta Bio, Inc. (NASDAQ:CABA) By 47%?
|
|
Dec 19
|
Cabaletta Bio Stock (NASDAQ:CABA): Analysts Expect More Gains Despite Massive Rally
|